Bio News
Endorobotics selected Mirae Asset Securities as its preferred negotiating partner for lead underwriting of its listing.
Endorobotics will continue preparations for a listing, targeting an initial public offering (IPO) in the second half of 2028.
Endorobotics plans to decide whether to sign a final underwriting agreement after negotiations with Mirae Asset Securities.
Biobook Team
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
